Literature DB >> 8590042

The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.

L A Anderson1, J J Anderson, T N Chase, J R Walters.   

Abstract

The effect of cannabinoid receptor stimulation on rotational behavior induced by a dopamine D1 and a D2 agonist was studied in rats with unilateral 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal pathway. The cannabinoid agonists WIN 55,212-2 (2.5 mg/kg) and CP 55,940 (0.1 mg/kg) both markedly attenuated contralateral rotation induced by the D1 agonist SKF 38393 (1.5 mg/kg). In contrast, WIN 55,212-2 and CP 55,940 did not alter rotation elicited by the D2 agonist quinpirole (0.1 mg/kg). Doses of WIN 55,212-2 and CP 55,940 that attenuated D1-mediated rotation did not produce catalepsy in intact rats or in rats with 6-hydroxydopamine-induced lesions, indicating that the reduction in rotation produced by the cannabinoids was not due to a generalized motor impairment. In addition, the effective dose of WIN 55,212-2, but not CP 55,940, produced only a slight increase in ipsilateral rotation when administered alone, making it improbable that this ipsilateral tendency accounts for the reduction in D1-mediated contralateral rotation. These results suggest a preferential interaction between cannabinoid receptor stimulation and dopamine D1 receptor-mediated behavior.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590042     DOI: 10.1016/0006-8993(95)00645-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.

Authors:  F Rodríguez De Fonseca; M A Gorriti; A Bilbao; L Escuredo; L M García-Segura; D Piomelli; M Navarro
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

4.  Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

Authors:  Maria Grazia Morgese; Tommaso Cassano; Vincenzo Cuomo; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2007-08-22       Impact factor: 5.330

5.  Endocannabinoid modulation of dopaminergic motor circuits.

Authors:  Teresa Morera-Herreras; Cristina Miguelez; Asier Aristieta; José Ángel Ruiz-Ortega; Luisa Ugedo
Journal:  Front Pharmacol       Date:  2012-06-12       Impact factor: 5.810

Review 6.  Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Mol Neurodegener       Date:  2015-04-08       Impact factor: 14.195

Review 7.  Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.

Authors:  Mariana Babayeva; Haregewein Assefa; Paramita Basu; Sanjeda Chumki; Zvi Loewy
Journal:  Parkinsons Dis       Date:  2016-12-05

8.  Cannabinoids differentially modulate cortical information transmission through the sensorimotor or medial prefrontal basal ganglia circuits.

Authors:  Mario Antonazzo; Amaia Gutierrez-Ceballos; Irati Bustinza; Luisa Ugedo; Teresa Morera-Herreras
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.